Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity

Journal of General Virology

Volumn 94, Issue PART 11, 2013, Pages 2367-2392

  Smith, Geoffrey L ^a   Benfield, Camilla T O ^a,b   Maluquer de Motes, Carlos ^a   Mazzon, Michela ^a   Ember, Stuart W J ^a,c   Ferguson, Brian J ^a   Sumner, Rebecca P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; I KAPPA B; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 8; LYMPHOTOXIN; PATTERN RECOGNITION RECEPTOR; PROTEIN A 46; PROTEIN A 49; PROTEIN A 52; PROTEIN B 14; PROTEIN C 4; PROTEIN E 3; PROTEIN K 1; PROTEIN K 7; PROTEIN M 2; PROTEIN N 1; PROTEIN VCP; PROTEIN VH 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

GENETIC CODE; IMMUNE EVASION; IMMUNOGENICITY; INNATE IMMUNITY; INTERFERON INDUCTION; MAMMAL CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; VACCINIA VIRUS; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; HUMANS; IMMUNE EVASION; IMMUNOMODULATION; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE;

EID: 84885636903     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.055921-0     Document Type: Review

References (275)

1. Alcamí, A. (2003). Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3, 36-50.
2. Alcamí, A. & Smith, G. L. (1992). A soluble receptor for interleukin-1 β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167.
3. Alcamí, A. & Smith, G. L. (1995). Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69, 4633-4639.
4. Alcamí, A. & Smith, G. L. (1996a). A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93, 11029-11034.
5. Alcamí, A. & Smith, G. L. (1996b). Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Trends Microbiol 4, 321-326.
6. Alcamí, A. & Smith, G. L. (2002). The vaccinia virus soluble interferon-gamma receptor is a homodimer. J Gen Virol 83, 545-549.
7. Alcamí, A., Symons, J. A., Collins, P. D., Williams, T. J. & Smith, G. L. (1998). Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 160, 624-633.
8. Alcamí, A., Khanna, A., Paul, N. L. & Smith, G. L. (1999). Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 80, 949-959.
9. Alcamí, A., Symons, J. A. & Smith, G. L. (2000). The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74, 11230-11239.
10. Alejo, A., Ruiz-Argüello, M. B., Ho, Y., Smith, V. P., Saraiva, M. & Alcamí, A. (2006). A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 103, 5995-6000.
11. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
12. Aoyagi, M., Zhai, D., Jin, C., Aleshin, A. E., Stec, B., Reed, J. C. & Liddington, R. C. (2007). Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 16, 118-124.
13. Bahar, M. W., Kenyon, J. C., Pütz, M. M., Abrescia, N. G., Pease, J. E., Wise, E. L., Stuart, D. I., Smith, G. L. & Grimes, J. M. (2008). Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 4, e5.
14. Banadyga, L., Veugelers, K., Campbell, S. & Barry, M. (2009). The fowlpox virus BCL-2 homologue, FPV039, interacts with activated Bax and a discrete subset of BH3-only proteins to inhibit apoptosis. J Virol 83, 7085-7098.
15. Baraz, L., Khazanov, E., Condiotti, R., Kotler, M. & Nagler, A. (1999). Natural killer (NK) cells prevent virus production in cell culture. Bone Marrow Transplant 24, 179-189.
16. Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002). The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83, 1965-1976.
17. Bartlett, N. W., Buttigieg, K., Kotenko, S. V. & Smith, G. L. (2005). Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86, 1589-1596.
18. Baxby, D. (1981). Jenner's Smallpox Vaccine. The Riddle of the Origin of Vaccinia Virus. London: Heinemann.
19. Beard, P. M., Froggatt, G. C. & Smith, G. L. (2006). Vaccinia virus kelch protein A55 is a 64 kDa intracellular factor that affects virusinduced cytopathic effect and the outcome of infection in a murine intradermal model. J Gen Virol 87, 1521-1529.
20. Beattie, E., Tartaglia, J. & Paoletti, E. (1991). Vaccinia virus-encoded eIF-2α homolog abrogates the antiviral effect of interferon. Virology 183, 419-422.
21. Benfield, C. T., Mansur, D. S., McCoy, L. E., Ferguson, B. J., Bahar, M. W., Oldring, A. P., Grimes, J. M., Stuart, D. I., Graham, S. C. & Smith, G. L. (2011). Mapping the IkappaB kinase β (IKKβ)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKβ-mediated activation of nuclear factor κB. J Biol Chem 286, 20727-20735.
22. Benfield, C. T., Ren, H., Lucas, S. J., Bahsoun, B. & Smith, G. L. (2013). Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol 94, 1647-1657.
23. Benhnia, M. R., McCausland, M. M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koriazova, L., Kubo, R., Kato, S. & Crotty, S. (2009). Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 83, 1201-1215.
24. Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. (1984). Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311, 578-579.
25. Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1986). Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 57, 786-791.
26. Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1987). Antiinfluenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol 61, 1098-1102.
27. Blanchard, T. J., Alcamí, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
28. Bogunovic, D., Byun, M., Durfee, L. A., Abhyankar, A., Sanal, O., Mansouri, D., Salem, S., Radovanovic, I., Grant, A. V. & other authors (2012). Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 337, 1684-1688.
29. Born, T. L., Morrison, L. A., Esteban, D. J., VandenBos, T., Thebeau, L. G., Chen, N., Spriggs, M. K., Sims, J. E. & Buller, R. M. (2000). A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 164, 3246-3254.
30. Bowie, A., Kiss-Toth, E., Symons, J. A., Smith, G. L., Dower, S. K. & O'Neill, L. A. (2000). A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 97, 10162-10167.
31. Brandt, T. A. & Jacobs, B. L. (2001). Both carboxy-and aminoterminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75, 850-856.
32. Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q., Nieva, J., Hwang, T. H., Moon, A. & other authors (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102.
33. Brooks, C. R., Elliott, T., Parham, P. & Khakoo, S. I. (2006). The inhibitory receptor NKG2A determines lysis of vaccinia virus-infected autologous targets by NK cells. J Immunol 176, 1141-1147.
34. Brum, L. M., Lopez, M. C., Varela, J. C., Baker, H. V. & Moyer, R. W. (2003). Microarray analysis of A549 cells infected with rabbitpox virus (RPV): a comparison of wild-type RPV and RPV deleted for the host range gene, SPI-1. Virology 315, 322-334.
35. Brutkiewicz, R. R., Klaus, S. J. & Welsh, R. M. (1992). Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cellmediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression. Nat Immun 11, 203-214.
36. Bukowski, J. F., Woda, B. A., Habu, S., Okumura, K. & Welsh, R. M. (1983). Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 131, 1531-1538.
37. Burns, J. M., Dairaghi, D. J., Deitz, M., Tsang, M. & Schall, T. J. (2002). Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem 277, 2785-2789.
38. Calderara, S., Xiang, Y. & Moss, B. (2001). Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology 279, 22-26.
39. Carfí, A., Smith, C. A., Smolak, P. J., McGrew, J. & Wiley, D. C. (1999). Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc Natl Acad Sci U S A 96, 12379-12383.
40. Carrara, G., Saraiva, N., Gubser, C., Johnson, B. F. & Smith, G. L. (2012). Six-transmembrane topology for Golgi anti-apoptotic protein (GAAP) and Bax inhibitor 1 (BI-1) provides model for the transmembrane Bax inhibitor-containing motif (TMBIM) family. J Biol Chem 287, 15896-15905.
41. Carroll, K., Elroy-Stein, O., Moss, B. & Jagus, R. (1993). Recombinant vaccinia virus K3L gene product prevents activation of doublestranded RNA-dependent, initiation factor 2α-specific protein kinase. J Biol Chem 268, 12837-12842.
42. Chang, H. W., Watson, J. C. & Jacobs, B. L. (1992). The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, doublestranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A 89, 4825-4829.
43. Charo, I. F. & Ransohoff, R. M. (2006). The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354, 610-621.
44. Chavan, R., Marfatia, K. A., An, I. C., Garber, D. A. & Feinberg, M. B. (2006). Expression of CCL20 and granulocyte-macrophage colonystimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 80, 7676-7687.
45. Chen, R. A., Jacobs, N. & Smith, G. L. (2006). Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87, 1451-1458.
46. Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4, e22.
47. Chisholm, S. E. & Reyburn, H. T. (2006). Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol 80, 2225-2233.
48. Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29-38.
49. Cohen, M. E., Xiao, Y., Eisenberg, R. J., Cohen, G. H. & Isaacs, S. N. (2011). Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS ONE 6, e20597.
50. Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A. & Buller, R. M. (1995). Vaccinia virus B18R gene encodes a type I interferonbinding protein that blocks interferon α transmembrane signaling. J Biol Chem 270, 15974-15978.
51. Cooray, S., Bahar, M. W., Abrescia, N. G., McVey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88, 1656-1666.
52. Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L. & Ahmed, R. (2003). Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171, 4969-4973.
53. Dai, K., Liu, Y., Liu, M., Xu, J., Huang, W., Huang, X., Liu, L., Wan, Y., Hao, Y. & Shao, Y. (2008). Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26, 5062-5071.
54. de Mattia, F., Gubser, C., van Dommelen, M. M., Visch, H. J., Distelmaier, F., Postigo, A., Luyten, T., Parys, J. B., de Smedt, H. & other authors (2009). Human Golgi antiapoptotic protein modulates intracellular calcium fluxes. Mol Biol Cell 20, 3638-3645.
55. DeHaven, B. C., Girgis, N. M., Xiao, Y., Hudson, P. N., Olson, V. A., Damon, I. K. & Isaacs, S. N. (2010). Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J Virol 84, 11245-11254.
56. Delano, M. L. & Brownstein, D. G. (1995). Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol 69, 5875-5877.
57. Dinarello, C. A. (2006). Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83, 447S-455S.
58. DiPerna, G., Stack, J., Bowie, A. G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar, S., Latz, E., Fitzgerald, K. A. & Marshall, W. L. (2004). Poxvirus protein N1L targets the I-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by toll-like receptors. J Biol Chem 279, 36570-36578.
59. Dobbelstein, M. & Shenk, T. (1996). Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 70, 6479-6485.
60. Dokun, A. O., Kim, S., Smith, H. R., Kang, H. S., Chu, D. T. & Yokoyama, W. M. (2001). Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2, 951-956.
61. Ember, S. W., Ren, H., Ferguson, B. J. & Smith, G. L. (2012). Vaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence. J Gen Virol 93, 2098-2108.
62. Engelstad, M. & Smith, G. L. (1993). The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194, 627-637.
63. Engelstad, M., Howard, S. T. & Smith, G. L. (1992). A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801-810.
64. + cytotoxic T lymphocytes and interferon-γ-producing T cells after smallpox vaccination. J Infect Dis 185, 1657-1659.
65. Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89, 2377-2387.
66. Falivene, J., Del Médico Zajac, M. P., Pascutti, M. F., Rodriguez, A. M., Maeto, C., Perdiguero, B., Gomez, C. E., Esteban, M., Calamante, G. & Gherardi, M. M. (2012). Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 7, e32220.
67. Fallon, P. G. & Alcamí, A. (2006). Pathogen-derived immunomodulatory molecules: future immunotherapeutics? Trends Immunol 27, 470-476.
68. Fang, M., Lanier, L. L. & Sigal, L. J. (2008). A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog 4, e30.
69. Fang, M., Orr, M. T., Spee, P., Egebjerg, T., Lanier, L. L. & Sigal, L. J. (2011). CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity 34, 579-589.
70. Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
71. Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organisation.
72. Ferguson, B. J., Mansur, D. S., Peters, N. E., Ren, H. & Smith, G. L. (2012). DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. eLife 1, e00047.
73. Ferguson, B. J., Benfield, C. T., Ren, H., Lee, V. H., Frazer, G. L., Strnadova, P., Sumner, R. P. & Smith, G. L. (2013). Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol 94, 2070-2081.
74. Flexner, C., Hugin, A. & Moss, B. (1987). Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259-262.
75. Froggatt, G. C., Smith, G. L. & Beard, P. M. (2007). Vaccinia virus gene F3L encodes an intracellular protein that affects the innate immune response. J Gen Virol 88, 1917-1921.
76. Fujioka, N., Akazawa, R., Ohashi, K., Fujii, M., Ikeda, M. & Kurimoto, M. (1999). Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol 73, 2401-2409.
77. Garber, D. A., O'Mara, L. A., Gangadhara, S., McQuoid, M., Zhang, X., Zheng, R., Gill, K., Verma, M., Yu, T. & other authors (2012). Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86, 12605-12615.
78. García, M. A., Guerra, S., Gil, J., Jimenez, V. & Esteban, M. (2002). Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21, 8379-8387.
79. García-Arriaza, J., Najera, J. L., Gomez, C. E., Sorzano, C. O. & Esteban, M. (2010). Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS ONE 5, e12395.
80. García-Arriaza, J., Najera, J. L., Gomez, C. E., Tewabe, N., Sorzano, C. O., Calandra, T., Roger, T. & Esteban, M. (2011). A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 6, e24244.
81. García-Calvo, M., Peterson, E. P., Leiting, B., Ruel, R., Nicholson, D. W. & Thornberry, N. A. (1998). Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273, 32608-32613.
82. Gardner, J. D., Tscharke, D. C., Reading, P. C. & Smith, G. L. (2001). Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model. J Gen Virol 82, 2083-2093.
83. Gedey, R., Jin, X. L., Hinthong, O. & Shisler, J. L. (2006). Poxviral regulation of the host NF-κB response: the vaccinia virus M2L protein inhibits induction of NF-κB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80, 8676-8685.
84. Gerlic, M., Faustin, B., Postigo, A., Yu, E. C.-W., Proell, M., Gombosuren, N., Krajewska, M., Flynn, R., Croft, M. & other authors (2013). Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci U S A 110, 7808-7813.
85. + NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog 7, e1002141.
86. Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P. & Paoletti, E. (1990). The complete DNA sequence of vaccinia virus. Virology 179, 247-266, 517-563.
87. Gomez, C. E., Najera, J. L., Krupa, M. & Esteban, M. (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8, 97-120.
88. Gomez, C. E., Perdiguero, B., Najera, J. L., Sorzano, C. O., Jimenez, V., Gonzalez-Sanz, R. & Esteban, M. (2012). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86, 5026-5038.
89. Gracie, J. A., Robertson, S. E. & McInnes, I. B. (2003). Interleukin-18. J Leukoc Biol 73, 213-224.
90. Graham, K. A., Lalani, A. S., Macen, J. L., Ness, T. L., Barry, M., Liu, L. Y., Lucas, A., Clark-Lewis, I., Moyer, R. W. & McFadden, G. (1997). The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology 229, 12-24.
91. Graham, S. C., Bahar, M. W., Abrescia, N. G., Smith, G. L., Stuart, D. I. & Grimes, J. M. (2007). Structure of CrmE, a virus-encoded tumour necrosis factor receptor. J Mol Biol 372, 660-671.
92. Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-κB rather than apoptosis. PLoS Pathog 4, e1000128.
93. Gubser, C. & Smith, G. L. (2002). The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J Gen Virol 83, 855-872.
94. Gubser, C., Hué, S., Kellam, P. & Smith, G. L. (2004). Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85, 105-117.
95. Gubser, C., Bergamaschi, D., Hollinshead, M., Lu, X., van Kuppeveld, F. J. & Smith, G. L. (2007). A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS Pathog 3, e17.
96. Guerra, S., Lopez-Fernandez, L. A., Conde, R., Pascual-Montano, A., Harshman, K. & Esteban, M. (2004). Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 78, 5820-5834.
97. Guerra, S., Caceres, A., Knobeloch, K. P., Horak, I. & Esteban, M. (2008). Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4, e1000096.
98. Haller, O., Kochs, G. & Weber, F. (2006). The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344, 119-130.
99. Hammaker, D., Boyle, D. L. & Firestein, G. S. (2012). Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology 51, 610-618.
100. Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., Hanifin, J. M. & Slifka, M. K. (2003). Duration of antiviral immunity after smallpox vaccination. Nat Med 9, 1131-1137.
101. Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A. & O'Neill, L. A. (2003). The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197, 343-351.
102. Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C. & other authors (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329-336.
103. Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E. & Fitzgerald, K. A. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514-518.
104. Howard, S. T., Chan, Y. S. & Smith, G. L. (1991). Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology 180, 633-647.
105. Hu, F. Q., Smith, C. A. & Pickup, D. J. (1994). Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204, 343-356.
106. Huang, J., Smirnov, S. V., Lewis-Antes, A., Balan, M., Li, W., Tang, S., Silke, G. V., Pütz, M. M., Smith, G. L. & Kotenko, S. V. (2007). Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A 104, 9822-9827.
107. Isaacs, A. & Lindenmann, J. (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147, 258-267.
108. Isaacs, A., Lindenmann, J. & Valentine, R. C. (1957). Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 147, 268-273.
109. Isaacs, S. N., Kotwal, G. J. & Moss, B. (1992a). Vaccinia virus complement-control protein prevents antibody-dependent complementenhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A 89, 628-632.
110. Isaacs, S. N., Wolffe, E. J., Payne, L. G. & Moss, B. (1992b). Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol 66, 7217-7224.
111. Jackson, R. J., Ramsay, A. J., Christensen, C. D., Beaton, S., Hall, D. F. & Ramshaw, I. A. (2001). Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75, 1205-1210.
112. Jackson, S. S., Ilyinskii, P., Philippon, V., Gritz, L., Yafal, A. G., Zinnack, K., Beaudry, K. R., Manson, K. H., Lifton, M. A. & other authors (2005). Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. J Virol 79, 6554-6559.
113. Jacobs, N., Chen, R. A., Gubser, C., Najarro, P. & Smith, G. L. (2006). Intradermal immune response after infection with Vaccinia virus. J Gen Virol 87, 1157-1161.
114. Jacobs, N., Bartlett, N. W., Clark, R. H. & Smith, G. L. (2008). Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection. J Gen Virol 89, 2877-2881.
115. Jacobs, B., Langland, J., Kibler, K., Denzler, K., White, S., Holechek, S., Wong, S., Huynh, T. & Baskin, C. (2009). Vaccinia virus vaccines: past, present and future. Antiviral Res 84, 1-13.
116. Jarahian, M., Fiedler, M., Cohnen, A., Djandji, D., Hammerling, G. J., Gati, C., Cerwenka, A., Turner, P. C., Moyer, R. W. & other authors (2011). Modulation of NKp30-and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog 7, e1002195.
117. Kalverda, A. P., Thompson, G. S., Vogel, A., Schröder, M., Bowie, A. G., Khan, A. R. & Homans, S. W. (2009). Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 385, 843-853.
118. Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13, 552-559.
119. Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T. & other authors (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28.
120. Kennedy, J. S., Frey, S. E., Yan, L., Rothman, A. L., Cruz, J., Newman, F. K., Orphin, L., Belshe, R. B. & Ennis, F. A. (2004). Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190, 1286-1294.
121. Kettle, S., Blake, N. W., Law, K. M. & Smith, G. L. (1995). Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206, 136-147.
122. Kettle, S., Alcamí, A., Khanna, A., Ehret, R., Jassoy, C. & Smith, G. L. (1997). Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1βconverting enzyme and protects virus-infected cells from TNF-and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J Gen Virol 78, 677-685.
123. Kibler, K. V., Shors, T., Perkins, K. B., Zeman, C. C., Banaszak, M. P., Biesterfeldt, J., Langland, J. O. & Jacobs, B. L. (1997). Doublestranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol 71, 1992-2003.
124. Kim, Y. G., Muralinath, M., Brandt, T., Pearcy, M., Hauns, K., Lowenhaupt, K., Jacobs, B. L. & Rich, A. (2003). A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci U S A 100, 6974-6979.
125. Kim, M. J., Hwang, S. Y., Imaizumi, T. & Yoo, J. Y. (2008). Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J Virol 82, 1474-1483.
126. Kirn, D. H. & Thorne, S. H. (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9, 64-71.
127. Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J. & Thorne, S. H. (2007). Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4, e353.
128. Kirwan, S., Merriam, D., Barsby, N., McKinnon, A. & Burshtyn, D. N. (2006). Vaccinia virus modulation of natural killer cell function by direct infection. Virology 347, 75-87.
129. Kohonen-Corish, M. R., King, N. J., Woodhams, C. E. & Ramshaw, I. A. (1990). Immunodeficient mice recover from infection with vaccinia virus expressing interferon-γ. Eur J Immunol 20, 157-161.
130. Kotwal, G. J. & Moss, B. (1988). Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335, 176-178.
131. Kotwal, G. J., Hugin, A. W. & Moss, B. (1989). Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171, 579-587.
132. Kvansakul, M., Yang, H., Fairlie, W. D., Czabotar, P. E., Fischer, S. F., Perugini, M. A., Huang, D. C. & Colman, P. M. (2008). Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 15, 1564-1571.
133. Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. N Engl J Med 281, 1201-1208.
134. Lanier, L. L. (2005). NK cell recognition. Annu Rev Immunol 23, 225-274.
135. Lee, D. F. & Hung, M. C. (2008). Advances in targeting IKK and IKKrelated kinases for cancer therapy. Clin Cancer Res 14, 5656-5662.
136. Legrand, F. A., Verardi, P. H., Jones, L. A., Chan, K. S., Peng, Y. & Yilma, T. D. (2004). Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol 78, 2770-2779.
137. Lehmann, M. H., Kastenmuller, W., Kandemir, J. D., Brandt, F., Suezer, Y. & Sutter, G. (2009). Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 83, 2540-2552.
138. Locksley, R. M., Killeen, N. & Lenardo, M. J. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501.
139. Lu, G., Reinert, J. T., Pitha-Rowe, I., Okumura, A., Kellum, M., Knobeloch, K. P., Hassel, B. & Pitha, P. M. (2006). ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol Biol 52, 29-41.
140. Luo, J. L., Kamata, H. & Karin, M. (2005). IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115, 2625-2632.
141. Lustig, S., Fogg, C., Whitbeck, J. C. & Moss, B. (2004). Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328, 30-35.
142. Lysakova-Devine, T., Keogh, B., Harrington, B., Nagpal, K., Halle, A., Golenbock, D. T., Monie, T. & Bowie, A. G. (2010). Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol 185, 4261-4271.
143. Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79, 7415-7419.
144. Maluquer de Motes, C., Cooray, S., Ren, H., Almeida, G. M., McGourty, K., Bahar, M. W., Stuart, D. I., Grimes, J. M., Graham, S. C. & Smith, G. L. (2011). Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7, e1002430.
145. Mann, B. A., Huang, J. H., Li, P., Chang, H. C., Slee, R. B., O'Sullivan, A., Anita, M., Yeh, N., Klemsz, M. J. & other authors (2008). Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res 28, 367-380.
146. Mansur, D. S., Maluquer de Motes, C., Unterholzner, L., Sumner, R. P., Ferguson, B. J., Ren, H., Strnadova, P., Bowie, A. G. & Smith, G. L. (2013). Poxvirus targeting of E3 ligase β-TrCP by molecular mimicry: a mechanism to inhibit NF-κB activation and promote immune evasion and virulence. PLoS Pathog 9, e1003183.
147. Marié, I., Durbin, J. E. & Levy, D. E. (1998). Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17, 6660-6669.
148. Marq, J. B., Hausmann, S., Luban, J., Kolakofsky, D. & Garcin, D. (2009). The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA-and DNA-induced activation of interferon β. J Biol Chem 284, 25471-25478.
149. Martinez, J., Huang, X. & Yang, Y. (2010). Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog 6, e1000811.
150. Mazzon, M., Peters, N. E., Loenarz, C., Krysztofinska, E. M., Ember, S. W., Ferguson, B. J. & Smith, G. L. (2013). A mechanism for induction of a hypoxic response by vaccinia virus. Proc Natl Acad Sci U S A 110, 12444-12449.
151. McCoy, S. L., Kurtz, S. E., Macarthur, C. J., Trune, D. R. & Hefeneider, S. H. (2005). Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLRdependent signaling and reduces in vivo bacterial-induced inflammation. J Immunol 174, 3006-3014.
152. McCoy, L. E., Fahy, A. S., Chen, R. A. & Smith, G. L. (2010). Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor κB activation. J Gen Virol 91, 2216-2220.
153. McKenzie, R., Kotwal, G. J., Moss, B., Hammer, C. H. & Frank, M. M. (1992). Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166, 1245-1250.
154. McMichael, A. J., Michie, C. A., Gotch, F. M., Smith, G. L. & Moss, B. (1986). Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67, 719-726.
155. Meng, X., Jiang, C., Arsenio, J., Dick, K., Cao, J. & Xiang, Y. (2009). Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol 83, 10627-10636.
156. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
157. Migita, K. & Nakamura, T. (2012). TBK1: a potential therapeutic target in RA. Rheumatology 51, 588-589.
158. Montanuy, I., Alejo, A. & Alcamí, A. (2011). Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses. FASEB J 25, 1960-1971.
159. Moore, J. B. & Smith, G. L. (1992). Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11, 1973-1980.
160. Moss, B. (2007). Poxviridae: the viruses and their replicaton. In Fields Virology, 5th edn, pp. 2905-2946. Edited by D. M. Knipe. Philadelphia: Lippincott Williams & Wilkins.
161. Moss, B. (2011). Smallpox vaccines: targets of protective immunity. Immunol Rev 239, 8-26.
162. Moss, B. & Salzman, N. P. (1968). Sequential protein synthesis following vaccinia virus infection. J Virol 2, 1016-1027.
163. Moss, B. & Shisler, J. L. (2001). Immunology 101 at poxvirus U: immune evasion genes. Semin Immunol 13, 59-66.
164. Mossman, K., Upton, C., Buller, R. M. & McFadden, G. (1995). Species specificity of ectromelia virus and vaccinia virus interferon-γ binding proteins. Virology 208, 762-769.
165. Moutaftsi, M., Tscharke, D. C., Vaughan, K., Koelle, D. M., Stern, L., Calvo-Calle, M., Ennis, F., Terajima, M., Sutter, G. & other authors (2010). Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 5, 221-239.
166. Myskiw, C., Arsenio, J., van Bruggen, R., Deschambault, Y. & Cao, J. (2009). Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-κB, and IRF3 pathways. J Virol 83, 6757-6768.
167. Najarro, P., Traktman, P. & Lewis, J. A. (2001). Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75, 3185-3196.
168. Natuk, R. J. & Welsh, R. M. (1987). Accumulation and chemotaxis of natural killer/large granular lymphocytes at sites of virus replication. J Immunol 138, 877-883.
169. Ng, A., Tscharke, D. C., Reading, P. C. & Smith, G. L. (2001). The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol 82, 2095-2105.
170. Nuara, A. A., Walter, L. J., Logsdon, N. J., Yoon, S. I., Jones, B. C., Schriewer, J. M., Buller, R. M. & Walter, M. R. (2008). Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFNγ-binding protein. Proc Natl Acad Sci U S A 105, 1861-1866.
171. Oda, S., Schröder, M. & Khan, A. R. (2009). Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure 17, 1528-1537.
172. Okeke, M. I., Nilssen, O. & Traavik, T. (2006). Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J Gen Virol 87, 21-27.
173. Osman, M., Kubo, T., Gill, J., Neipel, F., Becker, M., Smith, G., Weiss, R., Gazzard, B., Boshoff, C. & Gotch, F. (1999). Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 73, 6136-6140.
174. Paez, E. & Esteban, M. (1984). Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system. Virology 134, 12-28.
175. Paez, E. & Esteban, M. (1985). Interferon prevents the generation of spontaneous deletions at the left terminus of vaccinia virus DNA. J Virol 56, 75-84.
176. Paludan, S. R. & Bowie, A. G. (2013). Immune sensing of DNA. Immunity 38, 870-880.
177. Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79, 4927-4931.
178. Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80, 5364-5368.
179. Paoletti, E., Lipinskas, B. R., Samsonoff, C., Mercer, S. & Panicali, D. (1984). Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A 81, 193-197.
180. Parrish, S. & Moss, B. (2006). Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol 80, 553-561.
181. Parrish, S. & Moss, B. (2007). Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses. J Virol 81, 12973-12978.
182. Parrish, S., Resch, W. & Moss, B. (2007). Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc Natl Acad Sci U S A 104, 2139-2144.
183. Perera, L. P., Waldmann, T. A., Mosca, J. D., Baldwin, N., Berzofsky, J. A. & Oh, S. K. (2007). Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 81, 8774-8783.
184. Perkus, M. E., Piccini, A., Lipinskas, B. R. & Paoletti, E. (1985). Recombinant vaccinia virus: immunization against multiple pathogens. Science 229, 981-984.
185. Peters, N. E., Ferguson, B. J., Mazzon, M., Fahy, A. S., Krysztofinska, E., Arribas-Bosacoma, R., Pearl, L. H., Ren, H. & Smith, G. L. (2013). A mechanism for the inhibition of DNA-PK-mediated DNA sensing by vaccinia virus. PLoS Pathog 9, e1003649.
186. Pires de Miranda, M., Reading, P. C., Tscharke, D. C., Murphy, B. J. & Smith, G. L. (2003). The vaccinia virus kelch-like protein C2L affects calcium-independent adhesion to the extracellular matrix and inflammation in a murine intradermal model. J Gen Virol 84, 2459-2471.
187. Postigo, A. & Way, M. (2012). The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors. J Virol 86, 203-213.
188. Postigo, A., Cross, J. R., Downward, J. & Way, M. (2006). Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Differ 13, 1651-1662.
189. Price, N., Tscharke, D. C., Hollinshead, M. & Smith, G. L. (2000). Vaccinia virus gene B7R encodes an 18-kDa protein that is resident in the endoplasmic reticulum and affects virus virulence. Virology 267, 65-79.
190. Pulendran, B. & Ahmed, R. (2006). Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863.
191. Pulendran, B., Li, S. & Nakaya, H. I. (2010). Systems vaccinology. Immunity 33, 516-529.
192. Pütz, M. M., Alberini, I., Midgley, C. M., Manini, I., Montomoli, E. & Smith, G. L. (2005). Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 86, 2955-2960.
193. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315.
194. Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J. & other authors (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10, 116-125.
195. Randall, R. E. & Goodbourn, S. (2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89, 1-47.
196. Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath, P. R., Salvesen, G. S. & Pickup, D. J. (1992). Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 69, 597-604.
197. Reading, P. C. & Smith, G. L. (2003). Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77, 9960-9968.
198. Reading, P. C., Khanna, A. & Smith, G. L. (2002). Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 292, 285-298.
199. Reading, P. C., Moore, J. B. & Smith, G. L. (2003a). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197, 1269-1278.
200. Reading, P. C., Symons, J. A. & Smith, G. L. (2003b). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 170, 1435-1442.
201. Rehm, K. E. & Roper, R. L. (2011). Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. Vaccine 29, 3276-3283.
202. Rice, A. P. & Roberts, B. E. (1983). Vaccinia virus induces cellular mRNA degradation. J Virol 47, 529-539.
203. Rice, A. D., Turner, P. C., Embury, J. E., Moldawer, L. L., Baker, H. V. & Moyer, R. W. (2011). Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice. J Virol 85, 550-567.
204. Roberts, K. L. & Smith, G. L. (2008). Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16, 472-479.
205. Roper, R. L. (2006). Characterization of the vaccinia virus A35R protein and its role in virulence. J Virol 80, 306-313.
206. Rot, A. & von Andrian, U. H. (2004). Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22, 891-928.
207. Ruiz-Arguello, M. B., Smith, V. P., Campanella, G. S., Baleux, F., Arenzana-Seisdedos, F., Luster, A. D. & Alcamí, A. (2008). An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. J Virol 82, 917-926.
208. Saraiva, N., Prole, D. L., Carrara, G., de Motes, C. M., Johnson, B. F., Byrne, B., Taylor, C. W. & Smith, G. L. (2013a). Human and viral Golgi anti-apoptotic proteins (GAAPs) oligomerize via different mechanisms and monomeric GAAP inhibits apoptosis and modulates calcium. J Biol Chem 288, 13057-13067.
209. + entry and calpain 2. J Cell Biol 202, 699-713.
210. Schmidt, C. (2011). Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol 29, 295-296.
211. Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27, 2147-2157.
212. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A. & McFadden, G. (2003). Poxviruses and immune evasion. Annu Rev Immunol 21, 377-423.
213. Sharma, D. P., Ramsay, A. J., Maguire, D. J., Rolph, M. S. & Ramshaw, I. A. (1996). Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 70, 7103-7107.
214. Shisler, J. L. & Jin, X. L. (2004). The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IκBα degradation. J Virol 78, 3553-3560.
215. Silverman, R. H. (2007). Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 81, 12720-12729.
216. Smith, G. L. (1994). Virus strategies for evasion of the host response to infection. Trends Microbiol 2, 81-88.
217. Smith, G. L. & Chan, Y. S. (1991). Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol 72, 511-518.
218. Smith, G. L. & Moss, B. (1983). Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21-28.
219. Smith, G. L., Mackett, M. & Moss, B. (1983a). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495.
220. Smith, G. L., Murphy, B. R. & Moss, B. (1983b). Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80, 7155-7159.
221. Smith, G. L., Howard, S. T. & Chan, Y. S. (1989). Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J Gen Virol 70, 2333-2343.
222. Smith, G. L., Chan, Y. S. & Howard, S. T. (1991). Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J Gen Virol 72, 1349-1376.
223. Smith, C. A., Farrah, T. & Goodwin, R. G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962.
224. Smith, C. A., Hu, F. Q., Smith, T. D., Richards, C. L., Smolak, P., Goodwin, R. G. & Pickup, D. J. (1996). Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LTα. Virology 223, 132-147.
225. Smith, C. A., Smith, T. D., Smolak, P. J., Friend, D., Hagen, H., Gerhart, M., Park, L., Pickup, D. J., Torrance, D. & other authors (1997a). Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits β chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236, 316-327.
226. Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. & Alcamí, A. (1997b). Vaccinia virus immune evasion. Immunol Rev 159, 137-154.
227. Smith, G. L., Symons, J. A. & Alcamí, A. (1998). Poxviruses: interfering with interferon. Semin Virol 8, 409-418.
228. Smith, V. P., Bryant, N. A. & Alcamí, A. (2000). Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 81, 1223-1230.
229. Smith, G. L., Vanderplasschen, A. & Law, M. (2002). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83, 2915-2931.
230. Soulat, D., Burckstummer, T., Westermayer, S., Goncalves, A., Bauch, A., Stefanovic, A., Hantschel, O., Bennett, K. L., Decker, T. & Superti-Furga, G. (2008). The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J 27, 2135-2146.
231. Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R. M. & VanSlyke, J. (1992). Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71, 145-152.
232. Stack, J., Haga, I. R., Schröder, M., Bartlett, N. W., Maloney, G., Reading, P. C., Fitzgerald, K. A., Smith, G. L. & Bowie, A. G. (2005). Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201, 1007-1018.
233. + T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86, 1997-2006.
234. Stark, G. R. & Darnell, J. E., Jr (2012). The JAK-STAT pathway at twenty. Immunity 36, 503-514.
235. Sumner, R. P., Ren, H. & Smith, G. L. (2013). Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol 94, 1121-1126.
236. Sutter, G. & Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89, 10847-10851.
237. Symons, J. A., Alcamí, A. & Smith, G. L. (1995). Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551-560.
238. Symons, J. A., Adams, E., Tscharke, D. C., Reading, P. C., Waldmann, H. & Smith, G. L. (2002a). The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J Gen Virol 83, 2833-2844.
239. Symons, J. A., Tscharke, D. C., Price, N. & Smith, G. L. (2002b). A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence. J Gen Virol 83, 1953-1964.
240. Tait, S. W. & Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621-632.
241. Takahashi-Nishimaki, F., Funahashi, S., Miki, K., Hashizume, S. & Sugimoto, M. (1991). Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181, 158-164.
242. Tanaka-Kataoka, M., Kunikata, T., Takayama, S., Iwaki, K., Ohashi, K., Ikeda, M. & Kurimoto, M. (1999). In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 11, 593-599.
243. Tardif, J. C., L'Allier, P. L., Grégoire, J., Ibrahim, R., McFadden, G., Kostuk, W., Knudtson, M., Labinaz, M., Waksman, R. & other authors (2010). A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 3, 543-548.
244. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J. C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B. & other authors (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
245. Thacore, H. R. & Youngner, J. S. (1973). Rescue of vesicular stomatitis virus from interferon-induced resistance by superinfection with vaccinia virus. I. Rescue in cell cultures from different species. Virology 56, 505-511.
246. Thorne, S. H. (2011). Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 50, 286-293.
247. Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751-2755.
248. Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977-1986.
249. Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7, e1002247.
250. Upton, C., Macen, J. L., Wishart, D. S. & McFadden, G. (1990). Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 179, 618-631.
251. Upton, C., Mossman, K. & McFadden, G. (1992). Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science 258, 1369-1372.
252. Valentine, R. & Smith, G. L. (2010). Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J Gen Virol 91, 2221-2229.
253. van den Broek, M. F., Muller, U., Huang, S., Aguet, M. & Zinkernagel, R. M. (1995). Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol 69, 4792-4796.
254. Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. (1998). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 95, 7544-7549.
255. Verardi, P. H., Jones, L. A., Aziz, F. H., Ahmad, S. & Yilma, T. D. (2001). Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 75, 11-18.
256. Waibler, Z., Anzaghe, M., Frenz, T., Schwantes, A., Pohlmann, C., Ludwig, H., Palomo-Otero, M., Alcamí, A., Sutter, G. & Kalinke, U. (2009). Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 83, 1563-1571.
257. Walsh, S. R. & Dolin, R. (2011). Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 10, 1221-1240.
258. Wang, Z., Choi, M. K., Ban, T., Yanai, H., Negishi, H., Lu, Y., Tamura, T., Takaoka, A., Nishikura, K. & Taniguchi, T. (2008). Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNAsensing molecules. Proc Natl Acad Sci U S A 105, 5477-5482.
259. Wang, L. C., Lynn, R. C., Cheng, G., Alexander, E., Kapoor, V., Moon, E. K., Sun, J., Fridlender, Z. G., Isaacs, S. N. & other authors (2012). Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther 20, 736-748.
260. Wasilenko, S. T., Stewart, T. L., Meyers, A. F. & Barry, M. (2003). Vaccinia virus encodes a previously uncharacterized mitochondrialassociated inhibitor of apoptosis. Proc Natl Acad Sci U S A 100, 14345-14350.
261. Wasilenko, S. T., Banadyga, L., Bond, D. & Barry, M. (2005). The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation. J Virol 79, 14031-14043.
262. Wathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M. & Maniatis, T. (1998). Virus infection induces the assembly of coordinately activated transcription factors on the IFN-β enhancer in vivo. Mol Cell 1, 507-518.
263. Whitaker-Dowling, P. & Youngner, J. S. (1983). Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity. Virology 131, 128-136.
264. Wilcock, D., Duncan, S. A., Traktman, P., Zhang, W. H. & Smith, G. L. (1999). The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface. J Gen Virol 80, 2137-2148.
265. Williams, K. J., Wilson, E., Davidson, C. L., Aguilar, O. A., Fu, L., Carlyle, J. R. & Burshtyn, D. N. (2012). Poxvirus infection-associated downregulation of C-type lectin-related-b prevents NK cell inhibition by NK receptor protein-1B. J Immunol 188, 4980-4991.
266. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761-2767.
267. Wolffe, E. J., Isaacs, S. N. & Moss, B. (1993). Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol 67, 4732-4741.
268. Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. (2004). Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101, 4590-4595.
269. Wyatt, L. S., Earl, P. L., Vogt, J., Eller, L. A., Chandran, D., Liu, J., Robinson, H. L. & Moss, B. (2008). Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26, 486-493.
270. Xu, R., Johnson, A. J., Liggitt, D. & Bevan, M. J. (2004). Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 172, 6265-6271.
271. Xue, X., Lu, Q., Wei, H., Wang, D., Chen, D., He, G., Huang, L., Wang, H. & Wang, X. (2011). Structural basis of chemokine sequestration by CrmD, a poxvirus-encoded tumor necrosis factor receptor. PLoS Pathog 7, e1002162.
272. Yewdell, J. W., Bennink, J. R., Smith, G. L. & Moss, B. (1985). Influenza A virus nucleoprotein is a major target antigen for crossreactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82, 1785-1789.
273. Zhang, L., Derider, M., McCornack, M. A., Jao, S. C., Isern, N., Ness, T. & Moyer, R. (2006). Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1β. Proc Natl Acad Sci U S A 103, 13985-13990.
274. Zhao, C., Denison, C., Huibregtse, J. M., Gygi, S. & Krug, R. M. (2005). Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 102, 10200-10205.
275. Zhou, Q., Snipas, S., Orth, K., Muzio, M., Dixit, V. M. & Salvesen, G. S. (1997). Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem 272, 7797-7800.